Clinical and microbiological characteristics of rifampicin-resistant MRSA bacteraemia
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkac428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Seongman Bae und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Ko…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Bacteremia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Korea Health Technology R&D Project, Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Objectives
The clinical significance of rifampicin resistance in Staphylococcus aureus infections has not been demonstrated. Here, we evaluated the clinical characteristics of rifampicin-resistant S. aureus infection.
Methods
Data were collected from adult patients who were hospitalized with MRSA bacteraemia between March 2007 and May 2020 at a tertiary hospital in South Korea. The clinical characteristics and treatment outcomes of patients infected with rifampicin-resistant MRSA were compared with those of rifampicin-susceptible isolates. All-cause death and recurrence of MRSA infection were assessed for 90 days.
Results
Of the 961 patients with MRSA bacteraemia, 61 (6.3%) were infected by rifampicin-resistant isolates. The type of infection focus and duration of bacteraemia did not significantly differ between the two groups. Rifampicin-resistant MRSA isolates were more likely to have multidrug resistance and a higher vancomycin MIC relative to the rifampicin-susceptible isolates. The 90-day recurrence rate was higher in the patients infected with rifampicin-resistant MRSA compared with those with rifampicin-susceptible MRSA (18.0% versus 6.2%, P < 0.001), whereas the 90-day mortality was comparable between the two groups (27.9% versus 29.2%, P = 0.94). After adjusting for potential confounding factors, rifampicin resistance was significantly associated with 90-day recurrence (subdistributional HR: 2.31; 95% CI: 1.05–5.10; P = 0.04).
Conclusions
Rifampicin-resistant MRSA isolates showed distinct microbiological features in terms of multidrug resistance and a high vancomycin MIC. Although the management of MRSA bacteraemia was not significantly different between the two groups, recurrence was significantly more common in the rifampicin-resistant group. Rifampicin resistance may play a significant role in infection recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Yun Woo Lee
Förderung
- Korea Health Technology R&D Project
- Korea Health Industry Development Institute
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Bae, S., Kim, E. S., Lee, Y. W., Jung, J., Kim, M. J., Chong, Y. P., Kim, S. H., Choi, S. H., Lee, S. O., & Kim, Y. S. (2023). Clinical and microbiological characteristics of rifampicin-resistant MRSA bacteraemia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac428
Vancouver
Bae S, Kim ES, Lee YW, Jung J, Kim MJ, Chong YP, et al. Clinical and microbiological characteristics of rifampicin-resistant MRSA bacteraemia. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac428
BibTeX
@article{Bae2023,
author = {Bae, Seongman and Kim, Eun Sil and Lee, Yun Woo and Jung, Jiwon and Kim, Min Jae and Chong, Yong Pil and Kim, Sung-Han and Choi, Sang-Ho and Lee, Sang-Oh and Kim, Yang Soo},
title = {Clinical and microbiological characteristics of rifampicin-resistant MRSA bacteraemia},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkac428}
}
EUVIMED